|
1
|
Campanacci M, Baldini N, Boriani S and
Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg Am.
69:106–114. 1987.PubMed/NCBI
|
|
2
|
Anract P, De Pinieux G, Cottias P,
Pouillart P, Forest M and Tomeno B: Malignant giant-cell tumours of
bone. Clinico-pathological types and prognosis: a review of 29
cases. Int Orthop. 22:19–26. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gamberi G, Serra M, Ragazzini P, et al:
Identification of markers of possible prognostic value in 57 giant
cell tumors of bone. Oncol Rep. 10:351–356. 2003.PubMed/NCBI
|
|
4
|
Miszczyk L, Wydmanski J and Spindel J:
Efficacy of radiotherapy for giant cell tumor of bone: given either
postoperatively or as sole treatment. Int J Radiat Oncol Biol Phys.
49:1239–1242. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Olivera P, Perez E, Ortega A, et al:
Estrogen receptor expression in giant cell tumors of the bone. Hum
Pathol. 33:165–169. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Melillo G: Inhibiting hypoxia-inducible
factor 1 for cancer therapy. Mol Cancer Res. 4:601–605. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin SC, Liao WL, Lee JC and Tsai SJ:
Hypoxia-regulated gene network in drug resistance and cancer
progression. Exp Biol Med (Maywood). 239:779–792. 2014. View Article : Google Scholar
|
|
8
|
Cummins EP and Taylor CT:
Hypoxia-responsive transcription factors. Pflugers Arch.
450:363–371. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Licausi F, Weits DA, Pant BD, Scheible WR,
Geigenberger P and van Dongen JT: Hypoxia responsive gene
expression is mediated by various subsets of transcription factors
and miRNAs that are determined by the actual oxygen availability.
New Phytol. 190:442–456. 2011. View Article : Google Scholar
|
|
10
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Christofk HR, Vander Heiden MG, Harris MH,
et al: The M2 splice isoform of pyruvate kinase is important for
cancer metabolism and tumour growth. Nature. 452:230–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang GL, Jiang BH, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl
Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar
|
|
13
|
Pouysségur J, Dayan F and Mazure NM:
Hypoxia signalling in cancer and approaches to enforce tumour
regression. Nature. 441:437–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kaelin WG Jr and Ratcliffe PJ: Oxygen
sensing by metazoans: the central role of the HIF hydroxylase
pathway. Mol Cell. 30:393–402. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Blancher C, Moore JW, Talks KL, Houlbrook
S and Harris AL: Relationship of hypoxia-inducible factor
(HIF)-1alpha and HIF-2alpha expression to vascular endothelial
growth factor induction and hypoxia survival in human breast cancer
cell lines. Cancer Res. 60:7106–7113. 2000.
|
|
16
|
Zhong H, De Marzo AM, Laughner E, et al:
Overexpression of hypoxia-inducible factor 1alpha in common human
cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
17
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pralhad T, Madhusudan S and Rajendrakumar
K: Concept, mechanisms and therapeutics of angiogenesis in cancer
and other diseases. J Pharm Pharmacol. 55:1045–1053. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Taylor RM, Kashima TG, Knowles HJ and
Athanasou NA: VEGF, FLT3 ligand, PlGF and HGF can substitute for
M-CSF to induce human osteoclast formation: implications for giant
cell tumour pathobiology. Lab Invest. 92:1398–1406. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Knowles HJ and Athanasou NA:
Hypoxia-inducible factor is expressed in giant cell tumour of bone
and mediates paracrine effects of hypoxia on monocyte-osteoclast
differentiation via induction of VEGF. J Pathol. 215:56–66. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wülling M, Delling G and Kaiser E: The
origin of the neoplastic stromal cell in giant cell tumor of bone.
Hum Pathol. 34:983–993. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Morgan T, Atkins GJ, Trivett MK, et al:
Molecular profiling of giant cell tumor of bone and the
osteoclastic localization of ligand for receptor activator of
nuclear factor kappaB. Am J Pathol. 167:117–128. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Skubitz KM, Cheng EY, Clohisy DR, Thompson
RC and Skubitz AP: Gene expression in giant-cell tumors. J Lab Clin
Med. 144:193–200. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Atkins GJ, Haynes DR, Graves SE, et al:
Expression of osteoclast differentiation signals by stromal
elements of giant cell tumors. J Bone Miner Res. 15:640–649. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cowan RW, Singh G and Ghert M: PTHrP
increases RANKL expression by stromal cells from giant cell tumor
of bone. J Orthop Res. 30:877–884. 2012. View Article : Google Scholar
|
|
27
|
Xu M, Song ZG, Xu CX, et al: IL-17A
stimulates the progression of giant cell tumors of bone. Clin
Cancer Res. 19:4697–4705. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rao VH, Singh RK, Delimont DC, et al:
Transcriptional regulation of MMP-9 expression in stromal cells of
human giant cell tumor of bone by tumor necrosis factor-alpha. Int
J Oncol. 14:291–300. 1999.PubMed/NCBI
|
|
29
|
Kumta SM, Huang L, Cheng YY, Chow LT, Lee
KM and Zheng MH: Expression of VEGF and MMP-9 in giant cell tumor
of bone and other osteolytic lesions. Life Sci. 73:1427–1436. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kudo N, Ogose A, Ariizumi T, et al:
Expression of bone morphogenetic proteins in giant cell tumor of
bone. Anticancer Res. 29:2219–2225. 2009.PubMed/NCBI
|
|
31
|
Ambros V: MicroRNA pathways in flies and
worms: growth, death, fat, stress and timing. Cell. 113:673–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brennecke J, Hipfner DR, Stark A, Russell
RB and Cohen SM: bantam encodes a developmentally regulated
microRNA that controls cell proliferation and regulates the
proapoptotic gene hid in Drosophila. Cell. 113:25–36. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Reinhart BJ, Slack FJ, Basson M, et al:
The 21-nucleotide let-7 RNA regulates developmental timing in
Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gregory RI and Shiekhattar R: MicroRNA
biogenesis and cancer. Cancer Res. 65:3509–3512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Iorio MV and Croce CM: microRNA
involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhao L, Chen X and Cao Y: New role of
microRNA: carcinogenesis and clinical application in cancer. Acta
Biochim Biophys Sin (Shanghai). 43:831–839. 2011. View Article : Google Scholar
|
|
38
|
Fan L, Wu Q, Xing X, Wei Y and Shao Z:
MicroRNA-145 targets vascular endothelial growth factor and
inhibits invasion and metastasis of osteosarcoma cells. Acta
Biochim Biophys Sin (Shanghai). 44:407–414. 2012. View Article : Google Scholar
|
|
39
|
Duan Z, Choy E, Harmon D, et al:
MicroRNA-199a-3p is down-regulated in human osteosarcoma and
regulates cell proliferation and migration. Mol Cancer Ther.
10:1337–1345
|
|
40
|
Pan Z, Sun X, Shan H, et al: MicroRNA-101
inhibited postinfarct cardiac fibrosis and improved left
ventricular compliance via the FBJ osteosarcoma
oncogene/transforming growth factor-beta1 pathway. Circulation.
126:840–850. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yuan J, Chen L, Chen X, Sun W and Zhou X:
Identification of serum microRNA-21 as a biomarker for
chemosensitivity and prognosis in human osteosarcoma. J Int Med
Res. 40:2090–2097. 2012. View Article : Google Scholar
|
|
42
|
van der Deen M, Taipaleenmaki H, Zhang Y,
et al: MicroRNA-34c inversely couples the biological functions of
the runt-related transcription factor RUNX2 and the tumor
suppressor p53 in osteosarcoma. J Biol Chem. 288:21307–21319. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mao JH, Zhou RP, Peng AF, et al:
microRNA-195 suppresses osteosarcoma cell invasion and migration in
vitro by targeting FASN. Oncol Lett. 4:1125–1129. 2012.PubMed/NCBI
|
|
44
|
Fasanaro P, Greco S, Lorenzi M, et al: An
integrated approach for experimental target identification of
hypoxia-induced miR-210. J Biol Chem. 284:35134–35143. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mizuno Y, Tokuzawa Y, Ninomiya Y, et al:
miR-210 promotes osteoblastic differentiation through inhibition of
AcvR1b. Febs Lett. 583:2263–2268. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ramakrishnan A, Torok-Storb B and Pillai
MM: Primary marrow-derived stromal cells: isolation and
manipulation. Methods Mol Biol. 1035:75–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang XH, Zhao FJ, Han BM, et al: Primary
stromal cells isolated from human various histological/pathological
prostate have different phenotypes and tumor promotion role. Chin
Med J (Engl). 124:1700–1707. 2011.
|
|
48
|
Zhao JH, Luo Y, Jiang YG, He DL and Wu CT:
Knockdown of β-Catenin through shRNA cause a reversal of EMT and
metastatic phenotypes induced by HIF-1α. Cancer Invest. 29:377–382.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
50
|
Mutharasan RK, Nagpal V, Ichikawa Y and
Ardehali H: microRNA-210 is upregulated in hypoxic cardiomyocytes
through Akt- and p53-dependent pathways and exerts cytoprotective
effects. Am J Physiol Heart Circ Physiol. 301:H1519–H1530. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Biswas S, Roy S, Banerjee J, et al:
Hypoxia inducible microRNA 210 attenuates keratinocyte
proliferation and impairs closure in a murine model of ischemic
wounds. Proc Natl Acad Sci USA. 107:6976–6981. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Riggi N, Suvà ML, De Vito C, et al:
EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate
mesenchymal stem cell reprogramming toward Ewing sarcoma cancer
stem cells. Genes Dev. 24:916–932. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ban J, Jug G, Mestdagh P, et al:
Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a
positive feedback loop in Ewing's sarcoma. Oncogene. 30:2173–2180.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zuntini M, Salvatore M, Pedrini E, et al:
MicroRNA profiling of multiple osteochondromas: identification of
disease-specific and normal cartilage signatures. Clin Genet.
78:507–516. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mosakhani N, Pazzaglia L, Benassi MS, et
al: MicroRNA expression profiles in metastatic and non-metastatic
giant cell tumor of bone. Histol Histopathol. 28:671–678. 2013.
|
|
56
|
Vogel S, Wottawa M, Farhat K, et al:
Prolyl hydroxylase domain (PHD) 2 affects cell migration and
F-actin formation via RhoA/rho-associated kinase-dependent cofilin
phosphorylation. J Biol Chem. 285:33756–33763. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Fujita N, Markova D, Anderson DG, et al:
Expression of prolyl hydroxylases (PHDs) is selectively controlled
by HIF-1 and HIF-2 proteins in nucleus pulposus cells of the
intervertebral disc: distinct roles of PHD2 and PHD3 proteins in
controlling HIF-1alpha activity in hypoxia. J Biol Chem.
287:16975–16986. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Demidenko ZN and Blagosklonny MV: The
purpose of the HIF-1/PHD feedback loop: to limit mTOR-induced
HIF-1alpha. Cell Cycle. 10:1557–1562. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kelly TJ, Souza AL, Clish CB and
Puigserver P: A hypoxia-induced positive feedback loop promotes
hypoxia-inducible factor 1alpha stability through miR-210
suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol Cell
Biol. 31:2696–2706. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Krock BL, Skuli N and Simon MC:
Hypoxia-induced angio-genesis: good and evil. Genes Cancer.
2:1117–1133. 2011. View Article : Google Scholar
|
